NCT06951646 2026-03-09
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Second Xiangya Hospital of Central South University
Phase 2 Recruiting
Second Xiangya Hospital of Central South University
Memorial Sloan Kettering Cancer Center
University of British Columbia
Shanghai Chest Hospital